tapebrief
UHS · Q1 2026

UHS · Q2 2026 Earnings

Cautious

Universal Health Services

Reported July 28, 2026

30-second summary

Q2 FY2026 revenue of $4.638B (+8.3% YoY) beat consensus of $4.58B by 1.3%, but non-GAAP EPS of $5.98 missed the $6.02 consensus by 0.7% — the first EPS miss in the covered series. Q2 results included a favorable net pre-tax impact of ~$72M ($100M Florida DPP retroactive benefit for the Oct 1, 2024–Sept 30, 2025 period, pursuant to CMS's April 2026 preprint approval that increased the program size, offset by a $28M self-insurance reserve increase); neither item was in the original February forecast. More consequential is the FY2026 revenue guide, whose midpoint at $18.632B is just +0.2% above the original February midpoint of $18.603B despite Q2 revenue beating consensus and the $100M Florida DPP retroactive benefit landing in-quarter. That is a hidden trim: the retroactive DPP flowed into Q2 but the FY midpoint barely moved, and the range narrowed with Medicaid supplemental program uncertainty explicitly cited for periods beyond September 30, 2025.

Headline numbers

EPS

Q2 FY2026

$5.98

-0.7% vs est.

Revenue

Q2 FY2026

$4.64B

+8.3% YoY

+1.3% vs est.

Operating margin

Q2 FY2026

11.1%

Key financials

Q2 FY2026
MetricQ2 FY2026Q2 FY2025YoYQ1 FY2026QoQ
Revenue$4.64B$4.28B+8.3%$4.50B+3.2%
EPS$5.98$5.35+11.8%$5.62+6.4%
Operating margin11.1%11.7%-60bps11.2%-10bps

Guidance

Company revises FY2026 guidance modestly downward amid Medicaid supplemental payment program uncertainty and H1 2026 operating trends; Q2 revenue beat but EPS missed consensus.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

Actuals vs prior guidance

MetricPeriodPrior guideActualΔResult
RevenueQ2 FY2026—$4.638 billion+1.3% above consensus estimateBeat
Adjusted EPS (non-GAAP)Q2 FY2026—$5.98-0.7% below consensus estimate of $6.02Missed

New guidance

MetricPeriodGuideYoY
RevenueFY2026$18.501 billion to $18.762 billion—
Adjusted EPS (non-GAAP)FY2026$22.28 to $23.65—
Adjusted EBITDA, net of NCIFY2026$2.610 billion to $2.717 billion—
Capital ExpendituresFY2026$950 million to $1.1 billion—

Segment KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Acute Care Services$2.61B—+8.2%
Behavioral Health Care Services$1.929B$1.883B+2.4%

Other KPIs

Q2 FY2026
SegmentQ2 FY2026Q2 FY2025YoY
Adjusted Admissions (Acute Care)+2.9%——
Adjusted Patient Days (Acute Care)+3.1%——
Revenue Per Adjusted Admission (Acute Care)+3.0%——
Adjusted Admissions (Behavioral Health)+0.5%——
Adjusted Patient Days (Behavioral Health)+1.4%——
Revenue Per Adjusted Admission (Behavioral Health)+7.1%——
Adjusted EBITDA net of NCI$677.9M——
Adjusted EBITDA Margin14.6%——

Management tone

Narrative arc: Q3 FY2025 bullish Cedar Hill reframe → Q4 FY2025 conservative FY26 anchor with named headwinds → Q1 FY2026 strategic pivot via Talkspace with guide reiterated on faith → Q2 FY2026 first FY26 cut with Medicaid supplemental uncertainty (post-Sept 30, 2025) named.

Three quarters ago management was raising the FY25 EPS midpoint by $1.30 on a Q3 print; two quarters ago it anchored FY26 conservatively at $23.58 with ~$110M of named headwinds; last quarter it defended the same $23.58 on faith; this quarter it cut the midpoint to $22.965. The company's own framing — "we are revising our operating results forecast" based on "operating trends, changes in reimbursements related to certain Medicaid supplemental payment programs and financial results experienced during the first six months" — is the most measured phrasing management could offer for what is functionally a mid-year cut. The pivot from "raising" language to "revising" language, paired with the explicit CMS approval caveat, signals reimbursement visibility has deteriorated rather than operating results.

The Medicaid supplemental program language has bifurcated: the base Florida program was approved (CMS April 2026 preprint) and delivered a $100M Q2 retroactive tailwind for the Oct 1, 2024–Sept 30, 2025 period; but incremental benefit from an expanded program for periods beyond September 30, 2025 is explicitly excluded from the revised forecast because "CMS has not yet approved the increased size of this program for periods beyond September 30, 2025." Same class of program that produced the FY25 upside — now with the forward extension flagged as a source of downside risk if CMS doesn't approve.

The behavioral volume narrative has quietly stopped being asserted. Q4 FY2025 committed to 2-3% adjusted patient days for FY26; Q1 FY2026 restated the commitment as "more balanced between volume and pricing as the year progresses"; Q2 FY2026 delivered +1.4%, moving the wrong direction. There is no transcript this quarter, so no management defense is available — but four consecutive quarters of sub-+2% behavioral patient days, against a stated 2-3% target, is the cleanest evidence that the Talkspace acquisition was necessary because organic behavioral growth is not on track.

Answers to last quarter's watch list

Whether the FY2026 revenue/EPS guide is raised at Q2 FY2026. The opposite happened. Revenue midpoint moved +$29M (+0.2%), effectively a trim given the $100M Florida DPP retroactive benefit absorbed into Q2; EPS midpoint was cut $0.62 (-2.6%); EBITDA midpoint cut $51M (-1.9%). Management cited Medicaid supplemental program uncertainty for periods beyond Sept 30, 2025, not operating shortfall.
Resolved negatively
Behavioral same-facility adjusted patient days trajectory. +1.4%, below Q1's +1.6%. Fourth consecutive quarter below the 2-3% target management set for FY26. The Talkspace-as-growth-rescue framing is now the base case, not the hedge.
Resolved negatively
ACA exchange volume — does the steepening actually arrive? No specific exchange erosion figure appears in the press release, and without a transcript, the ACA cadence cannot be validated this quarter.
Not resolved
Talkspace deal close timing and any initial integration metric. Press release confirms Talkspace acquisition is expected to be finalized during Q3 2026, with a $400M delayed draw term loan A earmarked for closing. No integration metrics disclosed. Status: Partial — close timing confirmed, no integration data
Acute pricing run-rate — does the ex-DPP +4.9% hold? No — acute same-facility revenue per adjusted admission landed at +3.0% in Q2 (vs +4.6% for the six-month period), squarely inside the 3-4% FY26 assumption. Volume did the work in Q2 instead. Status: Resolved negatively (for the bull case)
Core growth bridge in Q2 FY2026 disclosure. Without a transcript, no bridge is available; the press release quantifies the $100M Florida DPP retroactive benefit and $28M insurance reserve as the two named items but does not decompose weather, flu, or exchange contributions. Status: Partial
Florida DPP approval timing and sizing. Florida DPP was approved (CMS April 2026 preprint), delivering a $100M favorable Q2 pre-tax impact for the Oct 1, 2024–Sept 30, 2025 period, with an increased program size and revised provider tax structure. The open question is whether CMS approves the expanded program size for periods beyond Sept 30, 2025 — management has excluded that incremental benefit from the revised forecast. Status: Resolved (base period); Continue monitoring (forward extension)

What to watch into next quarter

Whether the FY2026 EPS midpoint holds at $22.965 or gets cut further. The Q2 cut was explicitly Medicaid-driven and excludes incremental benefit from CMS's pending program expansion beyond Sept 30, 2025. A Q3 print that further trims the range — or a CMS decision that comes in unfavorably — would confirm the cliff has moved forward.

Behavioral adjusted patient days at Q3 — the fifth consecutive test of the 2-3% commitment. Four quarters below target now; another sub-+2% print effectively retires the organic growth thesis and puts the entire behavioral segment narrative on Talkspace integration.

Acute admissions and patient days above +3%. Q2 delivered +2.9% and +3.1% respectively — the cleanest volume acceleration in the coverage window and well above the 1.4%/1.9% H1 pace. If Q3 sustains this, acute volume takes over from pricing as the segment's growth engine.

Talkspace deal close and any disclosed cross-referral metric. Close now confirmed for Q3 2026 with the $400M delayed draw term loan A. A close without disclosed integration progress metrics extends the strategic-narrative skepticism.

CMS decision on Florida Medicaid supplemental payment program expansion for periods beyond September 30, 2025. Management has removed the incremental benefit from the forecast — a favorable decision is the cleanest FY26 upside catalyst; an unfavorable decision confirms the trim.

Any explicit ACA exchange volume erosion figure. The FY26 guide bakes in $75M pre-tax impact. H2 was supposed to be when the "steepening" arrived; without a Q3 quantification, that assumption remains a black box.

Sources

  1. UHS Q2 FY2026 press release, exhibit 99.1: https://www.sec.gov/Archives/edgar/data/352915/000119312526318940/uhs-ex99_1.htm
  2. UHS Q1 FY2026, Q4 FY2025, Q3 FY2025, Q2 FY2025 Tapebrief briefs for prior guide and watch-list comparison

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.